| Oct 2 |
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
|
| Sep 19 |
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
|
| Aug 29 |
Immix Biopharma Independent Director Acquires 2.6% More Stock
|
| Aug 28 |
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
|
| Aug 19 |
What Makes Immix Biopharma (IMMX) a New Buy Stock
|
| Jul 26 |
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
|
| Jul 8 |
Immix Biopharma doses first patient in U.S. AL amyloidosis trial
|
| Jul 8 |
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
|
| Jun 17 |
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
|
| Jun 10 |
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
|
